Latest Breaking News On - Signal detection study - Page 1 : comparemela.com

HARMONY BIOSCIENCES ANNOUNCES POSITIVE PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PRADER-WILLI SYNDROME AT SLEEP 2023

/PRNewswire/ Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative.

United statesKumar budurSusan hedstromLuis sanayPaige rivardFoundation for prader willi researchParagon biosciencesResearch symposiumUnited states national convention in orlandoPrnewswire harmony biosciences holdings incDrug administrationExchange commissionPrader willi syndrome association united statesBiosciences holdingsAnnual meetingAssociated professional sleep societies

Harmony Biosciences (HRMY) Reports Positive Phase 2 Signal Detection Study Data

Harmony Biosciences (HRMY) Reports Positive Phase 2 Signal Detection Study Data
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSusan hedstromKumar budurPaige rivardPrader willi syndrome associationUnited states national conventionHarmony biosciences holdings incResearch symposiumFoundation for prader willi researchBiosciences holdingsAnnual meetingAssociated professional sleep societiesEpworth sleepiness scaleChief medical officerExecutive directorPrader willi research

HARMONY BIOSCIENCES TO PRESENT NEW WAKIX® (PITOLISANT) SAFETY AND EFFICACY DATA AT SLEEP 2023 ANNUAL MEETING

Late-breaking Phase 2 proof-of-concept study in Prader-Willi syndrome accepted for poster presentation PLYMOUTH MEETING, Pa., May 10, 2023 /PRNewswire/ Harmony Biosciences Holdings, Inc. , a. | May 10, 2023

United statesKumar budurLuis sanayDrug administrationExchange commissionParagon biosciencesPrnewswire harmony biosciences holdings incLate breaking phaseBiosciences holdingsAnnual meetingAssociated professional sleep societiesChief medical officerMeaningful improvementsPooled analysisRandomized clinical trialsPresentation date

Phase 2 Results of Pitolisant in Prader-Willi Syndrome

Harmony Biosciences will present new efficacy data from a phase 2 study evaluating pitolisant in patients with Prader-Willi syndrome.

Kumar budurDrug administrationHarmony biosciences holdings incMeaningful improvementsPooled analysisRandomized clinical trialsPresentation dateBoard numberSafety resultsPlacebo controlled proofSignal detection studyPrader willi syndrome